Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis Report, Regional Outlook with Key Players – NOVO NORDISK, ELI-LILLY, SANOFI, ASTRAZENECA, GLAXOSMITHKLINE PLC F., HOFFMANN-LA ROCHE

Coherent Market Insights has announced the addition of the “Glucagon-Like Peptide-1 (Glp-1) Analogs Market Size Status and Forecast 2026”, The report classifies the global Glucagon-Like Peptide-1 (Glp-1) Analogs Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Glucagon-Like Peptide-1 (Glp-1) Analogs Speaker market, analyzes and researches the Glucagon-Like Peptide-1 (Glp-1) Analogs Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Novo Nordisk, Eli-Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., Hoffmann-La Roche Ltd.

Request a sample copy : https://www.coherentmarketinsights.com/insight/request-sample/1252

Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional anti-diabetic medication is propelling the growth of the market. GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy) which is the major factor restraining growth of the market. Also, there is an issue of patient compliance. For instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic medications, which are taken orally in tablet form.

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Also, GLP-1 analogs provide weight reduction benefit.

According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

On the basis of drug:

Exenatide
Liraglutide
Lixisenatide
Dulaglutide
Semaglutide
Albiglutide

On the basis of distribution channel:

Retail Pharmacy
Hospital pharmacy

On the basis of geography:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo Nordisk in October 2017 received FDA approval for once-a-week GLP-1 analog semaglutide. GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits. Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due to high gastrointestinal side effects and hypersensitivity reactions.

"If you have any special requirements, please let us know and we will offer you the report as you want."

Else place an Inquire before Purchase “Glucagon-Like Peptide-1 (Glp-1) Analogs Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1252

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.